Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • Cardiology-CTVS
  • Cardiology & CTVS Perspective
  • Impact of Azelnidipine...

Impact of Azelnidipine in reducing urinary albumin excretion and carotid atherosclerosis in type 2 diabetes patients: BOAT 2 study Review

Written By : Dr. Prem Aggarwal |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2020-12-15T12:45:35+05:30  |  Updated On 19 Oct 2023 5:19 PM IST
Impact of Azelnidipine in reducing urinary albumin excretion and carotid atherosclerosis in type 2 diabetes patients: BOAT 2 study Review
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

Hypertension and Diabetes Mellitus are the global health burden and strong risk factors for coronary artery disease (1). Impaired glucose tolerance and insulin resistance are associated with hypertension which in turn leads to the development of diabetes in hypertensive patients. This causes inflammation which leads to atherosclerosis and thus leading to an increased risk of cerebrovascular and cardiovascular diseases. Coexistence of both hypertension and diabetes increases the risk of cardiovascular diseases by 2-3fold (2). The risk of these life- threatening diseases escalates with the presence of other complications like diabetic nephropathy.

There is a wide variety of anti-hypertensive drugs that are used to control blood pressure including calcium channel blockers, renin-angiotensin system inhibitors (angiotensin II receptor blockers [ARBs] and angiotensin-converting enzyme [ACE] inhibitors), diuretics and β-blockers. α-blockers and central sympathetic nerve inhibitors are also administered additionally (3). Various studies in the past have shown that renin-angiotensin system blockers delay the progression of diabetic nephropathy and hence are recommended as the primary antihypertensive drugs (4,5). But as monotherapy may not be sufficient for effective blood pressure control, Combination therapy with other drugs is used.

Studies have also pointed out that in the presence of proteinuria, renin-angiotensin system inhibitors are the first choice of drugs. If proteinuria and diabetes are abseAvoiding Aldosterone Breakthrough in Hypertensive Diabetics: Role of Azelnidipinent, RAS inhibitors or calcium channel blockers or thiazide-type diuretics should be used (3).
Amlodipine:
Amlodipine is a synthetic dihydropyridine calcium channel blocker with antihypertensive and antianginal properties. It inhibits the influx of extracellular calcium ions into myocardial and peripheral vascular smooth muscle cells, thereby preventing vascular and myocardial contraction. This causes a dilatation of the main coronary and systemic arteries, decreased myocardial contractility, increased blood flow and oxygen delivery to the myocardial tissue, and a decreased total peripheral resistance (6).
Azelnidipine:
Azelnidipine is a dihydropyridine calcium channel blocker. It is marketed by Daiichi-Sankyo pharmaceuticals, Inc. in Japan. It has a gradual onset of action and produces a long-lasting decrease in blood pressure, with only a small increase in heart rate (7). Azelnidipine has profound renoprotective effects and antioxidant effects. It suppresses oxidative stress induced by Renin-Angiotensin-Aldosterone-System (RAAS) and has a beneficial effect on renal injury by reducing urinary protein excretion Combination therapy of
azelnidipine
with any RAAS inhibitor was found to have a potent renoprotective effect (8).
Considering the unique properties of azelnidipine like the antioxidant and anti-inflammatory effects, Kazuhito Tawaramoto et al conducted a study with a hypothesis that azelnidipine is more effective to delay the progression of atherosclerosis and/or diabetic nephropathy (9). The study was published as the letter to the editor in the journal "Diabetology & Metabolic Syndrome"
Methodology:
The study was a prospective, two-arm, randomized controlled clinical study with azelnidipine and amlodipine and was conducted in the division of Diabetes, Endocrinology and Metabolism in Kawasaki Medical School. A total of 38 patients with type 2 diabetes whose blood pressure was not sufficiently controlled by treatment with 20 mg/day of olmesartan for over 2 months were considered for the study. Insufficient blood pressure control was defined as having systolic blood pressure >130 mmHg and/or diastolic blood pressure >80 mmHg according to the guidelines by the Japanese Society of Hypertension.
Inclusion criteria were patients with type 2 diabetes and without well-controlled blood pressure by treatment with olmesartan, aged between 40-75 years old and having an HbA1c below 9.4 %. Patients with suspiciously secondary hypertension or non-diabetic kidney disease, with congenital dyslipidemia or extremely high LDL-cholesterol (>200 mg/dl), with advanced hepatic disease (AST >75 IU/ml) or advanced renal failure (Crn >2.0 mg/dl for male, Crn >1.5 mg/dl for female), pregnancy, or with a current history of any malignant neoplasm, using steroids or any medications like hormonal, diuretics, immune-suppressing medications and/or potassium drug or those with a past history of stroke or myocardial infarction occurring within past 6 months from the start of the trial were excluded from the study. There was no dropout during the follow-up period.
Patients were randomly divided into 2 groups where they were prescribed 16mg/day of azelnidipine and 5mg/day of amlodipine. The effects of both the drugs were evaluated after 32 weeks. Carotid IMT was measured and images of the carotid artery were scanned by computer and then analyzed. Various parameters like Plasma MCP-1, TNF-α, HMW adiponectin, leptin, soluble vascular cell adhesion molecule-1 (VCAM-1), soluble intercellular adhesion molecule-1 (ICAM-1) were measured using enzyme-linked immunosorbent assay kits. Statistical analysis was done.
Results:
The following results were noted
• There was no difference between the two groups in any clinical background including age, BMI, duration of diabetes, blood pressure and biochemical laboratory data except for heart rate.
• There was no difference between the two groups about the treatment of any anti- diabetic or anti-dyslipidemic medication.
• In both groups, systolic and diastolic blood pressure were significantly reduced during the trial (p >0.05), but the efficacy of lowering blood pressure was similar.
• Heart rate was significantly decreased only in azelnidipine group (p >0.05) and there was no statistically significant difference in heart rate between the two groups at the follow-up point.
• At baseline, there was no difference in glucose and lipid metabolism between the two groups.
• HbA1c, fasting plasma glucose and fasting plasma insulin levels were not altered during the treatment with azelnidipine or amlodipine.
• Plasma triglyceride, LDL-cholesterol and HDL-cholesterol levels were not altered.
• Max IMT was significantly decreased only in azelnidipine group at 32 weeks (p >0.05), although average IMT was not altered in both groups.
• Urinary albumin: At baseline, there was no difference in urinary albumin excretion between the two groups. Urinary albumin excretion was significantly reduced after azelnidipine treatment (p >0.05), but not after amlodipine treatment
. Urinary albumin excretion in azelnidipine group was significantly lowered compared to the amlodipine group (p > 0.05).
Thus, the authors observed that Azelnidipine causes reduction of urinary albumin excretion and carotid atherosclerosis. In the present study, the authors found that Azelnidipine reduced inflammatory factors like plasma MCP-1 and TNF-α which are key factors secreted by injured vascular cells in atherosclerosis.
The researchers also found from the study that azelnidipine does not affect theadipocytokines which are the key molecules for the improvement of urinary albumin excretion. By affecting the inflammatory axis rather than the adhesion molecules or adipocytokines, azelnidipine leads to the reduction of urinary albumin excretion and carotid atherosclerosis.
The authors suggested a further study with larger sample size, using a placebo, and evaluating the patients for habits like smoking.
" In summary, both azelnidipine (16 mg/day) and amlodipine (5 mg/day) have a similar ability to decrease blood pressure in hypertensive patients complicated with type 2 diabetes. However, azelnidipine delayed the progression of urinary albumin excretion and carotid atherosclerosis, which was not observed with amlodipine. We assume that the reduction of inflammation by azelnidipine explains, at least in part, its beneficial effects on urinary albumin excretion and carotid atherosclerosis," the authors concluded

The above article has been published by Medical Dialogues under the MD Brand Connect Initiative. For more details on Azelnidipine, click here

References:
1. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ. 2006;332(7533):73–78.
2. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension. 2001;37(4):1053–1059.
3. Umemura, S., Arima, H., Arima, S. et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertens Res 42, 1235–1481 (2019).
4. Abe, H., Mita, T., Yamamoto, R., Komiya, K., Kawaguchi, M., Sakurai, Y., Shimizu, T., Ohmura, C., Ikeda, F., Kawamori, R., Fujitani, Y., & Watada, H. (2013). Comparison of effects of cilnidipine and azelnidipine on blood pressure, heart rate and albuminuria in type 2 diabetics with hypertension: A pilot studyJournal of Diabetes Investigation, 4(2), 202-205.
5. Ogihara T, Kikuchi K, Matsuoka H, et al. The Japanese Society of Hypertension Committee for Guidelines for the Management of Hypertension. Hypertens Res 2009; 32: 4–5.
6. PubChem [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004-. PubChem Compound Summary for CID 2162, Amlodipine; [cited 2020 Sept. 14]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Amlodipine
7. PubChem [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004-. PubChem Compound Summary for CID 65948, Azelnidipine; [cited 2020 Sept. 14]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Azelnidipine
8. Ogawa S, Mori T, Nako K, Ito S. Combination therapy with renin-angiotensin system inhibitors and the calcium channel blocker azelnidipine decreases plasma inflammatory markers and urinary oxidative stress markers in patients with diabetic nephropathy. Hypertens Res 2008; 31: 1147–1155.
9. Tawaramoto, K., Kaneto, H., Hashiramoto, M., Kawasaki, F., Tatsumi, F., Shimoda, M., Kamei, S., Matsuki, M., Mune, T., & Kaku, K. (2015). Azelnidipine, but not amlodipine, reduces urinary albumin excretion and carotid atherosclerosis in subjects with type 2 diabetes: Blood pressure control with olmesartan and azelnidipine in Type 2 diabetes (BOAT2 study)Diabetology & metabolic syndrome, 7, 80.


azelnidipinetype 2 diabetesurinary albumin excretioncarotid atherosclerosisboat 2 studyhypertensiontheadipocytokinesatherosclerosisalbumin
Dr. Prem Aggarwal
Dr. Prem Aggarwal

Dr Prem Aggarwal, (MD Medicine, DNB Cardiology) is a Cardiologist by profession and also the Co-founder and Chairman of Medical. He focuses on news and perspectives about cardiology, and medicine related developments at Medical Dialogues. He can be reached out at drprem@medicaldialogues.in

Dr. Kamal Kant Kohli
Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

Show Full Article
Next Story

Editorial

Prediabetes and the Mind: Unraveling Cognitive and Mental Health Risks

Prediabetes and the Mind: Unraveling Cognitive and Mental Health Risks

Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer - Dr Aditya Murali

Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer...

Aspirin in Primary Prevention- When to Consider?

Aspirin in Primary Prevention- When to Consider?

Featured image representing medico legal

What's the Role of Expert Opinion in Medical Negligence?

7- Point Discharge Protocol for AECOPD: Time to Inculcate in Practice

7- Point Discharge Protocol for AECOPD: Time to Inculcate in Practice

View All

Journal Club Today

image representing junk food

Study Reveals Junk Food Ads Drive Higher Calorie Intake in Children

View All

Health News Today

Health Bulletin 13/ May/ 2025

Health Bulletin 13/ May/ 2025

View All
© 2022 All Rights Reserved.
Powered By: Hocalwire
X
We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok